Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 9609

GDF11 is an endogenous (meaning it’s natural, and you have it in you) signaling molecule whose primary mechanism of action is stem cell DNA repair. Most of the aging is likely caused by the atrophy of your stem cell populations due to declining GDF11 levels, and many believe this is natural selection’s way of programming lifespan. Fortunately, adding exogenous GDF11 can generally repair enough of senescent stem cells to reverse your age 5 to 10 years.

Steve will take some time providing information on the topic and answering questions.

“I’ve always been interested in stopping the aging process, and as a lifelong software guy, coupled with plenty of evidence from parabiosis experiments, I believe lifespan is programmed by natural selection, specifically group selection.

The primary mechanism for determining lifespan is a naturally occurring, blood born peptide called GDF11. Interestingly enough, the molecular structure of GDF11 is maintained across all vertebrate species. You have GDF in you right now, but unless you are 18, you don’t have enough of it.

Continue reading “Steve Perry presents GDF11 with an Age Reversal update” | >

“Human players must explicitly manage an ‘economy of attention’ to decide where to focus the camera,” said the DeepMind team. “However, analysis of AlphaStar’s games suggests that it manages an implicit focus of attention. On average, agents ‘switched context’ about 30 times per minute,” the team wrote, which was similar to Komincz’s and Wünsch’s behaviors.

Ultimately, the DeepMind team concluded that AlphaStar won against both pros because of “superior macro and micro-strategic decision-making, rather than superior click-rate, faster reaction times, or the raw interface.”

Read more

In the new paper, Jason Snyder, Ph.D., a University of British Columbia behavioral neuroscientist, argues that if you take a close look at all the studies on animals from mice to humans, the facts are quite clear: Animals probably don’t develop significant amounts of new brain cells as we enter adulthood. There’s still hope for some neurogenesis, but not a huge amount.

“In some respects, it’s just one of the things that humanity has always hoped for — staying young,” he tells Inverse. “So I think it’s been disconcerting that there might not be as many of these young cells that are malleable, that are adaptive, that are capable of learning earlier in life. Of course we want those things to be there, but I think that introduces some bias.”

To be clear, Snyder doesn’t argue that the field is biased. Instead, his argument is based on the analysis of past studies that have looked into this topic in humans, primates, and mice. There he admits that there’s been some confusion — some studies seem to show that the brain can continue to develop new cells later in life, while others show that it can’t. Specifically, he says that it’s been hard to let go of the idea of neurogenesis because of the results of animal studies (many on mice) “demonstrating persistent neurogenesis throughout life.”

Read more

  • In an age where innovative technologies like gene and cell therapy are transforming how we think about medical treatments, some CEOs are wondering what’s being left on the table.
  • Business Insider spoke to three companies developing new uses for old drugs, and they told us now might be a good time to rethink what we consider innovation.
  • Simply changing how drugs are dosed or delivered could open up the doors to more uses for existing medications in tough-to-treat conditions like female sexual arousal dysfunction or antibiotic-resistant infections.

The key to tackling hard-to-treat diseases could have less to do with flashy new technologies than with finding new uses for old drugs.

A range of smaller drugmakers are exploring the back catalogs of big pharma companies to discover old drugs that could be used in new ways, they told Business Insider. They’re seeking treatments for conditions including a rare lung disease, antibiotic-resistant infections, and female sexual arousal disorder. Along the way, they’re seeking to redefine what we think of as medical innovation.

Read more

NK-cell function appears to be impaired during spaceflights over long durations according to a new study published this week. This means that immune systems could be broken down somewhat during the long trips NASA hopes to take with astronauts in the distant future. The research here was done by a team of researchers at the University of Arizona, the University of Houston, Louisiana State University, and NASA-Johnson Space Center.

Read more

Artificial intelligence, or AI is something we hear a lot about today. In this interview with Life.

Extension’s Michael A. Smith, MD, Kristen Willeumier, PhD, provides some insight into AI technology and its relationship with psychiatry which, along with neurology, studies and treats diseases of the brain. Dr. Smith predicts that AI will soon be an important part of how we understand and treat disease. According to Dr. Willeumier, some of that technology is now “ready for prime time.” Download this Live Foreverish podcast episode for FREE on iTunes!

Artificial intelligence is, simply, the intelligence of machines as opposed to human or animal intelligence. According to the New World Encyclopedia™, “Artificial intelligence (AI) is a branch of computer science and engineering that deals with intelligent behavior, learning, and adaptation in machines. John McCarthy coined the term to mean ‘the science and engineering of making intelligent machines.’”.

Read more